RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.
The user has been using minoxidil, finasteride, dermastamping, and Nizoral for hair loss with initial success but is considering adding PRP due to slowed progress. Concerns about PRP include potential ineffectiveness and whether it could harm existing hair growth or interfere with current treatments.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
Temporal peaks are crucial for a natural-looking hair transplant, but they are challenging to achieve due to the need for precise angles and appropriate hair thickness. Many users emphasize the importance of finding a skilled surgeon and using finasteride to maintain hairline stability.
The user experienced increased hair shedding after adding tretinoin to their regimen of finasteride, minoxidil, and dermarolling, but noticed new vellus hairs appearing. They plan to restart tretinoin more gently, as some users suggest shedding indicates treatment effectiveness, while others warn it may cause severe thinning for a minority.
The user reintroduced RU58841 and noticed increased shedding and visible thinning. They have also been using dutasteride and oral minoxidil for 2 years.
Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.
The user is considering combining finasteride and minoxidil tablets into a topical solution that already includes Garnier Fructis stemoxydine and CB0103. They are seeking advice on whether this combination is effective and safe.
A user experienced significant hair loss after switching from topical to oral finasteride and minoxidil, despite initially seeing great results with the topical treatment. They are seeking advice on whether to return to topical treatments or increase their oral minoxidil dosage.
A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.
Stacking 5% minoxidil twice daily, 1.25mg finasteride daily, 6 drops of the Ordinary hair serum with Redensyl each night, 1.5mm dermarolling once a week, Nizoral shampoo twice a week and caffeine shampoo once a week for hair loss treatment.
A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.
The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.
The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.
The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.
The potential accuracy and trustworthiness of websites selling Pyrilutamide, a drug related to hair loss treatments such as Minoxidil, Finasteride, and RU58841; and whether Pyrilutamide is four times stronger than RU58841.
Exosome therapy for hair loss is questioned for its effectiveness and authenticity. Users express skepticism, citing manipulated photos and high costs.
A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.
User experienced slow gains with topical fin+min, switched to topical dut+min, and considered adding Eucapil. Another user suggested DUT may be less effective topically due to high molar mass and mentioned Fluridil as a weak anti-androgen that could help.
Hairgenetix Copper Peptide Serum and PeptideLabz GHK-Cu + AHK-Cu Serum are being compared for effectiveness in hair loss treatment. The user is seeking recommendations for other brands with authentic reviews.
A satirical discussion about a hair transplant, with humorous comments on graft placement and clinic choice. The conversation includes references to a "Rebuild a Scalp Clinic" and jokes about using pubic hair and overharvesting.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
People are discussing hair loss treatments, including finasteride, minoxidil, and dutasteride, focusing on maintenance and potential regrowth. Some users joke about unrealistic expectations, while others share experiences and advice on treatment options.
The conversation discusses Peptonix microneedling, a copper peptide serum, as a potential hair loss treatment. Users compare it to finasteride and minoxidil, noting side effects and personal experiences with these treatments.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
The conversation is about the effectiveness of Fluridil (Eucapil) for hair loss compared to RU58841, with the original poster considering Fluridil a safer and potentially more effective alternative.
PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.